Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Lymphangioma
ADR ID BADD_A07377
ADR Hierarchy
01      Blood and lymphatic system disorders
01.09      Spleen, lymphatic and reticuloendothelial system disorders
01.09.01      Lymphatic system disorders NEC
01.09.01.026      Lymphangioma
15      Musculoskeletal and connective tissue disorders
15.09      Musculoskeletal and connective tissue neoplasms
15.09.01      Benign musculoskeletal and connective tissue neoplasms
15.09.01.007      Lymphangioma
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.18      Soft tissue neoplasms benign
16.18.01      Soft tissue neoplasms benign NEC
16.18.01.009      Lymphangioma
24      Vascular disorders
24.09      Lymphatic vessel disorders
24.09.02      Lymphangiopathies
24.09.02.006      Lymphangioma
Description A benign tumor resulting from a congenital malformation of the lymphatic system. Lymphangioendothelioma is a type of lymphangioma in which endothelial cells are the dominant component. [MeSH]
MedDRA Code 10025219
MeSH ID D008202
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Lymphangioma | Lymphangioma, any site | Lymphangiomatosis | Lymphangiomas | Lymphangioendothelioma | Lymphangioendotheliomas | Endothelioma, Lymphatic | Endotheliomas, Lymphatic | Lymphatic Endothelioma | Lymphatic Endotheliomas | Lymphangioma, Cavernous | Cavernous Lymphangioma | Cavernous Lymphangiomas | Lymphangiomas, Cavernous
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01252Leflunomide0.000428%
BADD_D01265Levetiracetam0.000119%
BADD_D02028Sirolimus0.000523%
The 1th Page    1    Total 1 Pages